{"filing":{"accession_number":"0001472375-26-000167","cik":"0001357878","ticker":"RGPX","company_name":"REGENEREX PHARMA, INC.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"ixform8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1357878/000147237526000167/ixform8k.htm"},"events":[{"id":5451,"run_id":4775,"accession_number":"0001472375-26-000167","anchor_item_number":"5.02","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"summary":"The filing discloses commencement of legal proceedings by Regenerex Pharma against its former Chief Financial Officer, Kenneth W. Perry, seeking recovery of funds and other amounts allegedly owed, plus injunctive relief and damages. While filed under Item 5.02 (executive departures/appointments), the substantive disclosure centers on material litigation initiated by the company against a former executive officer, making this a material litigation event. The involvement of a CFO and allegations of misconduct during tenure would affect a reasonable investor's assessment of the company's governance and financial controls.","company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","filing_date":"2026-06-11","submitted_at":null,"items":[{"id":6189,"accession_number":"0001472375-26-000167","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"The filing discloses commencement of legal proceedings by Regenerex Pharma against its former Chief Financial Officer, Kenneth W. Perry, seeking recovery of funds and other amounts allegedly owed, plus injunctive relief and damages. While filed under Item 5.02 (executive departures/appointments), the substantive disclosure centers on material litigation initiated by the company against a former executive officer, making this a material litigation event. The involvement of a CFO and allegations of misconduct during tenure would affect a reasonable investor's assessment of the company's governance and financial controls.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T17:53:27.809788+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6189,"accession_number":"0001472375-26-000167","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"The filing discloses commencement of legal proceedings by Regenerex Pharma against its former Chief Financial Officer, Kenneth W. Perry, seeking recovery of funds and other amounts allegedly owed, plus injunctive relief and damages. While filed under Item 5.02 (executive departures/appointments), the substantive disclosure centers on material litigation initiated by the company against a former executive officer, making this a material litigation event. The involvement of a CFO and allegations of misconduct during tenure would affect a reasonable investor's assessment of the company's governance and financial controls.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T17:53:27.809788+00:00","company_name":"REGENEREX PHARMA, INC.","ticker":"RGPX","filing_date":"2026-06-11"}]}